Medtronic, Boston Scientific Corporation – Notable Market Players in Radiofrequency Ablation Devices Market
In a radiofrequency ablation procedure, the physician uses a device which transmits radiofrequency energy and destroys the target tissue. This technology has been widely used to treat solid tumors, arrhythmias, uterine fibroids and other medical conditions.
Market leaders operating in the market have undertaken various organic growth strategies in the radiofrequency ablation devices market. The radiofrequency ablation devices market majorly consists of the players such as Avanos Medical, Inc., Stryker, Abbott, Medtronic, Boston Scientific, Bard (BD), Angiodynamic, Hologic, Articure, Merit medical, among others. Several organic approaches, such as product launches, and expansion/relocation in the radiofrequency ablation devices market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market.
Below is the list of the growth strategies done by the players operating in the Radiofrequency Ablation Devices Market:
|
Year |
News |
|
Feb-20 |
Avanos Medical, Inc. received approval from the U.S. Food and Drug Administration (FDA) for marketing of its new, 80-Watt COOLIEF Radiofrequency (RF) system for neurological lesion procedures. This new device is easy-to-use; it is equipped with an advanced designed RF generator and other associated devices. |
|
Feb-19 |
Medtronic received approval from the FDA for the marketing of the Accurian radiofrequency ablation system, that is used for the treatment of chronic pain. This has helped the company strengthen its business segment operations in the US. |
|
Apr-17 |
The US Food and Drug Administration (FDA) approved Avanos Medical, Inc’s COOLIEF Cooled Radiofrequency (Cooled RF) thermal treatment for marketing. The applications for the relief of chronic moderate to severe knee pain due to osteoarthritis. It is the primary and only RF treatment that is explicitly cleared to relieve osteoarthritis knee pain |
|
Feb-17 |
Hologic Inc. launched a next-generation NovaSure ADVANCED global endometrial ablation (GEA) system in the US market. The FDA has approved the system sale in the US. This product approval has strengthened the company’s business in the US and benefited associated business operations. |
